CEO SUMMARY: Two unexpected things happened in IMPATH’s Chapter 11 bankruptcy action. First, it attracted a buyer willing to pay the premium price of $215 million for its assets. Second, the buyer was not another laboratory company. Rather, it is a new entrant into the oncology diagnostics marketplace. This raises interesting questions as to Genzyme’s […]
IMPATH Has a Buyer: Genzyme Pays $215 Mil
Latest entrant into oncology diagnostics may intensify marketplace competition
- By Robert Michel
- > From the Volume XI No. 4 - March 15, 2004 Issue
- Tags: ameripath, anatomic pathologist, Anatomic pathology, anatomic pathology services, cancer testing, cap, dark report, diagnostic lab, diagnostic laboratory, diagnostic laboratory tests, diagnostic testing, Diagnostic tests, diagnostics market, dianon systems, genetic test, genetic testing, genetic tests, genomics, hematology, impac, lab industry, lab test, lab testing, lab tests, laboratories, laboratory acquisitions, laboratory company, laboratory director, laboratory medicine, laboratory test, laboratory testing, laboratory testing services, laboratory tests, molecular diagnostic, molecular pathology, pathologists, pathology companies, Pathology group, pathology groups, pathology service, pathology services, pathology specimen, pathology specimens, specialty lab, specialty laboratories, tests for cancer, the dark report
